Semler Scientific, Inc. (SMLR)

Executive Summary / Key Takeaways

• Semler Scientific has completed a radical transformation from medical device manufacturer to Bitcoin treasury company, but the healthcare business that was supposed to fund this strategy is collapsing faster than expected, with Q4 2025 revenues projected to fall at least 60% from Q3's already-depressed $7.5 million level.
• The company's "dual-engine strategy" has become a single-engine gamble: two major customers representing 72% of Q3 revenue have announced they will cease using QuantaFlo devices, effectively ending the cash-generating healthcare business that management intended to use for Bitcoin acquisitions.
• Bitcoin holdings have created extreme earnings volatility and mask operational disaster—Q3 net income of $16.9 million was significantly boosted by $30 million in unrealized Bitcoin gains, which helped to offset an operating loss of $5.4 million from the core healthcare business, which itself generated -71.95% operating margins.
• The pending all-stock merger with Strive, Inc. at a 210% premium represents the only viable path forward, as the healthcare business faces both CMS reimbursement elimination and a $29.75 million DOJ settlement that has triggered new class action lawsuits.
• Semler Scientific now trades as a highly leveraged Bitcoin proxy: with 5,048 Bitcoin worth $575.8 million against a $274.7 million market cap, shareholders are effectively getting the Bitcoin exposure at a discount while the legacy healthcare business is valued at negative $300 million—if you believe the Bitcoin strategy is sustainable.

Setting the Scene: From PAD Screening to Digital Gold

Semler Scientific, incorporated in Delaware in 2007 and headquartered in Santa Clara, California, spent seventeen years building a niche medical device business around QuantaFlo, a patented, FDA-cleared system for rapid point-of-care arterial blood flow measurement. The company's mission centered on improving healthcare outcomes through early detection of chronic diseases like Peripheral Arterial Disease (PAD). This was a classic medtech story: develop a differentiated diagnostic tool, secure regulatory clearance, build recurring revenue through a SaaS model, and generate steady cash flows from an aging population with increasing cardiovascular disease prevalence.

That story ended in May 2024. Management abruptly adopted Bitcoin as its primary treasury reserve asset, becoming only the second U.S. public company to do so. The stated rationale was a "dual-engine strategy" where the healthcare business would generate cash flows to fund Bitcoin acquisitions, providing shareholders with amplified exposure to what management calls "digital gold." This wasn't a gradual pivot—it was a complete strategic reinvention that transformed Semler from a healthcare technology company into a leveraged Bitcoin speculation vehicle.

The problem is that one engine is now failing catastrophically. The 2024 CMS rate announcement eliminated risk-adjusted payments for PAD without complications, destroying the economic rationale for QuantaFlo usage among Medicare Advantage providers. The July 2017 DOJ investigation into False Claims Act violations culminated in a September 2025 settlement requiring $29.75 million in payments plus interest. These twin blows have reduced healthcare revenues by 44% year-over-year for three consecutive quarters, and management now anticipates Q4 revenues will be "at least 60% lower" than Q3's $7.5 million—implying quarterly healthcare revenue below $3 million, a level that cannot support the company's operating structure.

Technology and Strategic Differentiation: A Moat With No Water

QuantaFlo's technology genuinely offered differentiation in the PAD screening market. The device delivers a cuffless, four-minute blood flow measurement using volume plethysmography , generating a simple ratio-based score that requires minimal training. This simplicity enabled deployment in primary care settings where traditional ABI testing was impractical. The product held patent protection and faced no direct digital ABI competitors, creating what appeared to be a defensible niche in a $3.19 billion vascular diagnostics market growing at 7.3% annually.

Why does this matter? Because Semler's entire Bitcoin strategy was predicated on this moat generating consistent cash flows. The company explicitly stated that healthcare profits would fund Bitcoin acquisitions, creating a self-reinforcing cycle. The technology's ease-of-use and regulatory clearance were supposed to insulate it from competition and reimbursement pressure, providing the "engine" that would power the Bitcoin treasury.

That assumption has proven catastrophically wrong. The CMS reimbursement change didn't just reduce payments—it eliminated them entirely for uncomplicated PAD cases, which represented the majority of QuantaFlo's addressable market. The DOJ settlement, while resolving legal uncertainty, created reputational damage that accelerated customer attrition. Two customers alone accounted for 72% of Q3 revenue, and both have notified Semler they will cease device usage starting October 1, 2025. This concentration risk, always a vulnerability, has become an existential threat.

The company's response has been to form CardioVanta, Inc. in June 2025, a wholly-owned subsidiary targeting heart failure detection and cardiac arrhythmia monitoring. Management describes this as a multibillion-dollar market opportunity, but it remains pre-revenue and will require "modest initial capital needs" that Semler is ill-equipped to provide. The subsidiary plans to seek outside investors, acknowledging that the parent company cannot fund new healthcare initiatives while simultaneously pursuing aggressive Bitcoin accumulation targets.

Financial Performance: Accounting Gains Masking Operational Collapse

The financial statements tell a story of two entirely different businesses. For the nine months ended September 30, 2025, healthcare revenues collapsed 44% to $24.5 million while operating expenses surged 138% to $63.1 million, driven by a $29.8 million DOJ settlement reserve and increased legal and consulting costs. The healthcare segment generated an operating loss of $38.5 million compared to $17.4 million in operating income in the prior year period. Operating margins have fallen to -71.95%, a level that signals business model failure rather than temporary disruption.

Yet Semler reported net income of $19.1 million for the nine-month period, an increase of $7.4 million year-over-year. The Bitcoin "engine" generated $70.4 million in unrealized fair value gains, more than offsetting the healthcare segment's collapse. Q3 exemplifies this dynamic: the healthcare business lost $5.4 million from operations, but a $30 million Bitcoin gain significantly contributed to the reported $16.9 million in net income. This accounting treatment—recognizing Bitcoin price changes directly in earnings—creates extreme volatility and masks the underlying operational deterioration.

The balance sheet reveals the leverage strategy's scale. As of September 30, 2025, Semler held 5,048 Bitcoin with a fair value of $575.8 million and a cost basis of $478.9 million. Against this, the company has raised $215 million through at-the-market equity offerings, issued $100 million in 4.25% convertible senior notes due 2030, and borrowed $20 million from Coinbase Credit (COIN) at 10% interest, collateralized by 315 Bitcoin. Total current liabilities have ballooned to $27.2 million from $6.3 million at year-end 2024, while cash stands at just $10.3 million.

Why does this matter? Because Semler is now a highly leveraged Bitcoin derivative. The company has explicitly stated targets to accumulate 10,000 Bitcoin by year-end 2025, 42,000 by 2026, and 105,000 by 2027. Achieving these goals requires continuous capital raising through equity dilution and debt issuance. Management describes this as "intelligent leverage," but the strategy depends entirely on Bitcoin appreciation exceeding the cost of capital. If Bitcoin prices stagnate or decline, the company will face interest expenses and principal repayments with no operational cash flows to service them.

Competitive Context: A Unique but Unstable Position

Semler's competitive position must be evaluated on two dimensions: as a medical device company and as a Bitcoin treasury company.

In vascular diagnostics, Semler's QuantaFlo technology held a genuine differentiation advantage against traditional ABI devices from GE HealthCare (GEHC) and Philips (PHG), and even against portable ultrasound systems from Butterfly Network (BFLY). The cuffless, training-free approach enabled screening in primary care settings where competitors' more complex systems couldn't penetrate. However, this advantage proved fleeting when reimbursement disappeared. GEHC and PHG can absorb reimbursement pressure across diversified product portfolios; BFLY can pivot to other ultrasound applications. Semler's single-product dependence meant the reimbursement change was existential.

As a Bitcoin treasury company, Semler ranks 15th globally among public Bitcoin holders but 6th among companies "truly operating on a Bitcoin standard" by management's own metric. This positioning reflects both ambition and isolation. Unlike MicroStrategy (MSTR), which has a profitable software business generating $500 million in annual cash flow, Semler's healthcare engine is sputtering out. Unlike Tesla (TSLA) or Block (SQ), which hold Bitcoin as a treasury diversifier, Semler has made Bitcoin its primary strategic focus.

The competitive advantage Semler claims—being a public company that can issue low-cost debt and equity to acquire Bitcoin—depends entirely on investor appetite for its story. Management's quote about "97% of institutional capital being restricted to equities and credit" suggests they see themselves as a Bitcoin proxy for traditional investors. But this creates a reflexive vulnerability: if the healthcare business collapses completely, the narrative breaks, and the ability to raise capital disappears. The $500 million ATM program approved in April 2025 becomes worthless if investors lose confidence in the dual-engine story.

Outlook and Execution Risk: A Merger of Necessity

Management's guidance has become increasingly dire. The Q4 revenue forecast of "at least 60% lower" than Q3's $7.5 million implies quarterly healthcare revenue below $3 million—an 80% decline from the $12.4 million reported in Q4 2024. The company acknowledges it "will need to undertake measures to align expenses with the revenue decline," a euphemism for significant cost cuts or workforce reductions. The December 2025 workforce reduction announcement confirms this reality.

The strategic response has been the September 2025 merger agreement with Strive, Inc., an all-stock transaction where Semler shareholders receive 21.05 shares of Strive Class A common stock per Semler share. This agreement implies a value of approximately $90.52 per share, representing a 210% premium over the trading price on September 19, and a stark contrast to the current $17.99 price. Strive, presumably, sees value in Semler's Bitcoin holdings and remaining healthcare assets, while Semler's management likely concluded that standalone survival was impossible.

The merger reveals management's admission that the dual-engine strategy has failed. A successful healthcare business wouldn't need to merge at a premium to salvage value; it would continue generating cash for Bitcoin acquisitions. The fact that Semler is selling itself while simultaneously pursuing aggressive Bitcoin accumulation targets suggests the healthcare business is being abandoned, not repositioned.

The merger faces significant execution risks. It requires shareholder and antitrust approvals, and the merger agreement limits Semler's ability to pursue alternatives while subjecting it to a $49 million termination fee under certain circumstances. New class action lawsuits filed in August and October 2025 related to the DOJ settlement create additional legal overhang that could complicate or delay closing.

Valuation Context: Pricing a Broken Business Model

At $17.99 per share, Semler Scientific trades at a $274.7 million market capitalization. The valuation metrics are simultaneously meaningless and revealing:

• P/E ratio of 3.47x appears cheap but reflects Bitcoin gains, not sustainable earnings
• Price-to-book of 0.59x suggests the market values the company below its accounting equity
• EV/Revenue of 10.31x is high for a business in freefall
• Operating margin of -71.95% signals business model failure

The real valuation exercise is separating the Bitcoin assets from the healthcare liabilities. Semler's 5,048 Bitcoin have a fair value of $575.8 million against a cost basis of $478.9 million, representing $96.9 million in unrealized gains. Net of the $20 million Coinbase loan and $100 million convertible notes, the Bitcoin holdings have a net asset value exceeding $450 million—far above the $274.7 million market cap.

This implies the market is assigning negative value to the healthcare business, treating it as a liability that will consume capital rather than generate it. The valuation disconnect reflects investor skepticism about both the sustainability of the Bitcoin strategy and the potential for further healthcare losses. Management's claim that the stock is "absurdly undervalued" may be technically correct if you believe the Bitcoin holdings are secure and the healthcare business can be wound down without additional cash burn.

However, this valuation analysis ignores the leverage and custody risks. The $100 million convertible notes bear an effective interest rate of 5.09% and mature in 2030, requiring either refinancing or repayment. The $20 million Coinbase loan at 10% interest is collateralized by 315 Bitcoin, creating liquidation risk if Bitcoin prices fall below the loan-to-value threshold. The company acknowledges custody risks, including potential loss of access in bankruptcy proceedings.

Risks and Asymmetries: The Thesis Can Break in Both Directions

The investment thesis faces material risks that cut to the core of the dual-engine strategy:

Healthcare Revenue Collapse: The mechanism is straightforward—if Q4 revenue falls below $3 million and continues declining, the healthcare business will generate negative cash flow, becoming a drag rather than a funding source. This is not a hypothetical; management has explicitly guided to this outcome. The severity is extreme because it eliminates the strategic rationale for maintaining the healthcare operations at all.

Bitcoin Volatility and Leverage: The company's strategy depends on Bitcoin appreciation exceeding the cost of debt. If Bitcoin prices decline, Semler faces a triple threat: unrealized losses flowing through earnings, potential margin calls on the Coinbase loan, and inability to raise additional capital through equity offerings. The 10% interest rate on the $20 million Coinbase loan is particularly concerning given that the healthcare business cannot generate sufficient cash to service this debt.

Customer Concentration and Reputational Damage: With two customers representing 72% of revenue and both exiting, Semler has lost its installed base. The DOJ settlement and related class action lawsuits create reputational damage that will make customer acquisition nearly impossible, especially in the highly regulated Medicare Advantage market. This concentration risk has transitioned from a vulnerability to a realized catastrophe.

Merger Execution Risk: The Strive merger represents the only viable exit, but closing conditions, antitrust review, and the $49 million termination fee create multiple failure points. If the merger collapses, Semler would be left with a dying healthcare business and a Bitcoin strategy that requires continuous capital markets access.

Custody and Regulatory Risk: The company acknowledges that its custodially-held Bitcoin could become part of a custodian's insolvency estate in bankruptcy. With 315 Bitcoin pledged as collateral and the remainder held by third parties, Semler faces counterparty risk that pure Bitcoin holders can avoid through self-custody.

The asymmetry is stark: if Bitcoin surges and the merger closes, shareholders could see significant upside from both the premium and continued Bitcoin appreciation. If either leg fails, the downside includes potential insolvency as leverage becomes unserviceable and the healthcare business cannot be unwound without additional costs.

Conclusion: A Speculation, Not an Investment

Semler Scientific has become a case study in strategic overreach. The May 2024 decision to adopt Bitcoin as a primary treasury asset was predicated on a healthcare business that management believed could generate consistent cash flows. Eighteen months later, that business has collapsed under the weight of reimbursement elimination, legal settlements, and customer concentration risk. The "dual-engine strategy" has devolved into a single-engine speculation where shareholders are betting that Bitcoin appreciation will outweigh operational losses and leverage costs.

The pending Strive merger acknowledges this reality. At a 210% premium, it offers shareholders an exit from a broken business model, but the structure—an all-stock transaction—transfers the Bitcoin leverage and healthcare liabilities to Strive's balance sheet. The premium reflects the value of 5,048 Bitcoin, not the healthcare operations, which the market values at negative $300 million.

For investors, Semler Scientific is no longer a healthcare technology company but a highly leveraged, volatile Bitcoin proxy with a declining business attached. The 3.47x P/E ratio is meaningless because earnings are driven by Bitcoin mark-to-market adjustments, not operational performance. The relevant metrics are Bitcoin holdings per share, leverage ratios, and the timeline for healthcare business wind-down.

The central thesis hinges on two variables: whether the Strive merger closes successfully, and whether Bitcoin appreciation continues to outpace the cost of leverage. If both hold, the current discount to net asset value may offer upside. If either fails, shareholders face potential significant losses from a business model that has proven unsustainable. This is not a fundamentals-driven investment but a speculation on Bitcoin price momentum and merger arbitrage, suitable only for investors who understand the extreme risks of leverage, volatility, and operational collapse.